{
    "id": 50619,
    "name": "paranasal sinus cancer",
    "source": "DOID",
    "definition": "A respiratory system cancer that is located_in the paranasal sinuses. [url:http\\://www.cancer.gov/cancertopics/pdq/treatment/paranasalsinus/Patient/page1]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        "2442",
        "2767",
        "4689",
        "1354",
        "2765"
    ],
    "termId": "DOID:0050619",
    "evidence": [
        
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT02196168",
            "title": "Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 822,
                    "therapyName": "Adavosertib",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02538510",
            "title": "Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer and Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3077,
                    "therapyName": "Pembrolizumab + Vorinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02567422",
            "title": "VX-970, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced HPV-Negative Head and Neck Squamous Cell Carcinoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3109,
                    "therapyName": "Cisplatin + VX-970",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02795156",
            "title": "Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 998,
                    "therapyName": "Cabozantinib",
                    "synonyms": null
                },
                {
                    "id": 623,
                    "therapyName": "Afatinib",
                    "synonyms": null
                },
                {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02834013",
            "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors",
            "phase": "Phase 0",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03238365",
            "title": "Nivolumab With or Without Tadalafil in Treating Patients With Recurrent Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6100,
                    "therapyName": "Nivolumab + Tadalafil",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03370276",
            "title": "Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4761,
                    "therapyName": "Cetuximab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03381183",
            "title": "IRX-2 Regimen, Durvalumab, Tremelimumab for Incurable Head and Neck Squamous Cell Carcinoma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6590,
                    "therapyName": "Cyclophosphamide + Durvalumab + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03422536",
            "title": "Ficlatuzumab With or Without Cetuximab in Treating Patients With Cetuximab-Resistant, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 740,
                    "therapyName": "Ficlatuzumab",
                    "synonyms": null
                },
                {
                    "id": 1959,
                    "therapyName": "Cetuximab + Ficlatuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03719690",
            "title": "Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy (AIM-HN/SEQ-HN)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 938,
                    "therapyName": "Tipifarnib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04290546",
            "title": "CIML NK Cell in Head & Neck Cancer",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9454,
                    "therapyName": "ALT-803 + CIML-NK cells + Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 9455,
                    "therapyName": "ALT-803 + CIML-NK cells",
                    "synonyms": null
                }
            ]
        }
    ]
}